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Abstract
Objective:Rhabdomyolysis is a rare and potentially serious adverse drug reaction (ADR) to antipsychotic medicines. The aim
of this study was to investigate the clinical circumstances surrounding the diagnosis of rhabdomyolysis in children and
adolescents treated with antipsychotic medicines. We also critically reviewed individual case safety reports (ICSRs) of
suspected ADRs to evaluate how clinically useful they can be in a case series analysis.
Methods: This was a descriptive and an exploratory study. Published case reports and ICSRs from the World Health
Organization (WHO) Global ICSR database, VigiBase, reported with rhabdomyolysis and antipsychotic medicines for
patients £17 years years of age were described. Reporting patterns of ICSRs with rhabdomyolysis and antipsychotic
medicines were explored in VigiBase for children and adolescents and for adults. The VigiBase ICSRs were also system-
atically evaluated regarding the report content.
Results: Of the 26 evaluated reports, 6 co-reported neuroleptic malignant syndrome (NMS) and 20 reports concerned
rhabdomyolysis in the absence of NMS. The reported suspected antipsychotic medicines for these 20 reports were olanzapine,
risperidone, haloperidol, paliperidone, quetiapine, clozapine, cyamemazine, and aripiprazole. In VigiBase, rhabdomyolysis
(in the absence of NMS) was reported more frequently with olanzapine relative to all reports for children and adolescents with
antipsychotic medicines. In the range of events that preceded rhabdomyolysis, muscle pains and abdominal pain were
commonly recorded to have started during the week prior to the diagnosis. Other preceding symptoms were general weakness
and dark urine. Onset of rhabdomyolysis for most patients occurred at any time within 2 months of starting antipsychotic
treatment, in several cases triggered by changes to the patient’s drug therapy or known risk factors of rhabdomyolysis. It was
found that ICSRs can contribute with additional information, but that access to free text and narratives were crucial in order to
capture clinically useful features of rhabdomyolysis.
Conclusion: Monitoring of children and adolescents needs to be intensified during dose increases, or when a new, added, or
switched antipsychotic medicine is introduced to their drug regimen, and during exposure to known risk factors for rhab-
domyolysis. The development of seemingly nonserious events, such as abdominal pain, muscle pain, weakness, and dark
urine, should be followed up during antipsychotic use, as they might be precursory events to rhabdomyolysis that eventually
could develop into acute renal failure.
Introduction
Antipsychotic medicines, particularly the atypical,are increasingly being prescribed for children and adoles-
cents (Olfson et al. 2006; Rani et al. 2008). These medicines are
used for a range of psychiatric disorders such as schizophrenia,
psychosis, bipolar disorders, attention-deficit/hyperactivity disor-
ders (ADHD), autism, and conduct disorders (Cheng-Shannon et al.
2004), often outside licensed indications for younger age groups
(Pathak et al. 2010; Almandil et al. 2011). The high incidence of
adverse drug reactions (ADRs) induced by antipsychotics and the
suggested higher susceptibility of children to certain ADRs makes
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this continuous increase in use a concern (Correll et al. 2006; Jerrell
et al. 2008; Rani et al. 2009). Problematic and common ADRs seen
in the pediatric population with antipsychotic therapy are: weight
gain (Almandil et al. 2012); lipid and liver transaminase alterations,
particularly for olanzapine; more elevated prolactin levels for ris-
peridone; and more severe extrapyramidal symptoms for haloper-
idol (Sikich et al. 2004, 2008).
A rarer and potentially serious but less documented ADR
from antipsychotic medicines is rhabdomyolysis presenting in
the absence of neuroleptic malignant syndrome (NMS). Rhab-
domyolysis is caused by skeletal muscle destruction resulting in
leakage of muscle constituents into plasma. Clinical features of
the syndrome are myalgia, weakness, dark urine, elevated serum
creatine phosphokinase (CPK), and myoglobinuria, possibly
leading to acute renal failure and compartment syndrome
(Gabow et al. 1982; Elsayed et al. 2010). Common causes for
rhabdomyolysis are, specifically in children, viral myositis
(Mannix et al. 2006; Wu et al. 2009), and in adolescents, trauma
and drug overdose/reaction (Mannix et al. 2006). Illicit drugs/
alcohol, prescribed drugs, muscle diseases, trauma and NMS,
were the most common causes of rhabdomyolysis observed in a
study on 475 hospitalized child and adult patients. Eleven per-
cent of the rhabdomyolysis cases (in the absence of NMS) were
caused by ‘‘prescribed drugs,’’ of which haloperidol, atypical
antipsychotics, and phenothiazines were the most frequently
represented drugs (Melli et al. 2005).
Antipsychotic-induced rhabdomyolysis, in the absence of NMS,
has been highlighted in a limited number of published case reports
on children and adolescents (Yoshikawa et al. 2000; Rosebraugh
et al. 2001; Holtmann et al. 2003; Strawn et al. 2008; Hung et al.
2009; Karakaya et al. 2010). Detailed published case reports are a
valuable source of information to increase our understanding of a
clinical problem (Vandenbroucke 1999, 2001). These important
case histories can sometimes be our only data source on rare and
serious ADRs occurring in small subpopulations, such as children.
A potential additional source could be international pharmacov-
igilance reports collected during postmarketing drug use. In the
current study, we reviewed published case reports and pharma-
covigilance reports to investigate the clinical circumstances sur-
rounding the diagnosis of rhabdomyolysis in children and
adolescents taking antipsychotic medicines. We also critically
reviewed the use of pharmacovigilance reports in a clinical case
series analysis.
Methods
This was a descriptive and exploratory study using reports
of rhabdomyolysis occurring during treatment with antipsy-
chotic medicines in children and adolescents. The reports
consisted of published case reports and individual case safety
reports (ICSRs) from the World Health Organization (WHO)
Global ICSR database, VigiBase, maintained by Uppsala
Monitoring Centre, the WHO Collaborating Centre for Inter-
national Drug Monitoring (Lindquist 2008). Three analyses
were conducted:
1. An overview of disproportionate reporting patterns in Vigi-
Base of ICSRs for children and adolescents and for adults.
2. A case series analysis of published case reports and Vigi-
Base ICSRs, following detailed review of each case, which
included causality assessment of each report.
3. A critical review of the VigiBase ICSRs to determine their
clinical usefulness in a case series analysis.
VigiBase Dataset and Terminologies
Antipsychotic medicines in this study were classified according
to the WHO Anatomical Therapeutic Chemical (ATC) classifica-
tion group, N05A (WHO Collaborating Centre for Drug Statistics
Methodology 2009). VigiBase ICSRs coded with the Medical
Dictionary for Regulatory Activities (MedDRA) Preferred Term
(PT) rhabdomyolysis were retrieved (Maintenance and Support
Service Organization [MSSO] 2010). The focus of this article was
on rhabdomyolysis in the absence of NMS, therefore the reports
were separated in two groups:
 ICSRs with the MedDRA PT rhabdomyolysis reported
without neuroleptic malignant syndrome, referred to as the
‘‘RM group.’’
 ICSRs with the MedDRA PT rhabdomyolysis co-reported
with neuroleptic malignant syndrome, referred to as the
‘‘RM+NMS group.’’
For the ICSRs for £17 years of age, the complete ICSRs were
manually reviewed to confirm classification of the ICSR to the
‘‘RM group’’ and the ‘‘RM+NMS group.’’
The dataset used in this study includes ICSRs entered in Vigi-
Base up to February 5, 2010. At the time of the study, 97 countries
had contributed almost 5,000,000 ICSRs to VigiBase. The reports
are collected following marketing of a medicinal product, primarily
to detect safety problems that were not identified in premarketing
clinical studies. In the initial extraction of reports, an automated
screening of duplicates was applied (Nore´n et al. 2007). Duplica-
tion of reports can occur in large compilations of data when reports
of the same event are sent from more than one source.
Disproportionate Reporting Patterns in VigiBase
This quantitative evaluation was restricted to data available as
structured information in the VigiBase dataset. Associations be-
tween drugs and ADRs were identified using the Information
Component (IC). The IC is a measure of disproportionality, com-
puted as the logarithm of a shrinkage observed-to-expected ratio
(Bate et al. 1998; Nore´n et al. 2011). A positive IC value indicates
that a particular drug–ADR pair is reported more often than ex-
pected, based on all reports in the subgroups used in this study. The
IC025 value is the lower limit of a 95% credibility interval of the IC
and provides information about the robustness of a specific IC
value. The IC does not imply causality of a potential ADR and a
drug, but is used to highlight disproportionate reporting patterns for
further evaluation, using IC025 > 0 as the threshold.
To explore the overall reporting pattern of ICSRs for children
and adolescents (2–17 years) and for adults (‡18 years), the ob-
served-to-expected ratio was calculated for reports with antipsy-
chotic medicines and rhabdomyolysis co-reported with and without
NMS for each age group. The computed expected value was based
on the overall reporting of rhabdomyolysis with and without NMS
with any drug in each age group.
The reporting frequency for the three most commonly reported
suspected antipsychotic drug substances with rhabdomyolysis among
children and adolescents in VigiBase was explored. The relative re-
porting frequency was calculated for ICSRs with rhabdomyolysis, co-
reported with and without NMS, and each of the antipsychotic drug
substances relative to the overall reporting of the drug for children and
adolescents (2–17 years) and for adults (‡18 years). The lower limit of
the 95% credibility interval of the shrinkage observed-to-expected
ratio (Nore´n et al. 2011) was used to highlight disproportionate re-
porting of rhabdomyolysis with or without NMS with each of the
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suspected antipsychotic drug substances relative to the overall re-
porting of the defined terms with antipsychotic medicines in the age
group.
Detailed Case Series Analysis of VigiBase Original
Reports and Published Case Reports
For the detailed case series analysis, a systematic review of the
VigiBase ICSRs and the published case reports was performed and
a causality assessment of each report was conducted. For this
analysis, VigiBase original reports were used. If the VigiBase ICSR
existed also as a published case report, the published report was
used in the review. The data elements recommended to be con-
sidered when describing features of an adverse event report was
used as a guideline in the case series analysis (Kelly et al. 2007).
VigiBase individual case safety reports
Reports with the MedDRA PT rhabdomyolysis and an antipsy-
chotic medicine concerning patients £17 years of age were re-
trieved as previously described. The anonymous original VigiBase
case report files were requested and received from the national
pharmacovigilance centers contributing the reports, and were used
in the detailed case series analysis. A manual screening of sus-
pected duplicate reports was performed.
Published case reports
Case reports were screened in the literature to increase the
number of cases for review. In order to identify case reports we
searched multiple databases including: EMBASE (1980–2010
week 21), PubMed (1969–2010), BIOSIS (1969–2009 week 27),
and International Pharmaceutical Abstracts (1970 to May 2010)
using the search terms in Table 1. In addition, the reference sections
of all retrieved articles were manually searched for further relevant
publications. We included case reports of rhabdomyolysis in the
absence of NMS in children and adolescents 2–17 years of age
treated with antipsychotic drugs. We included all cases with serious
outcomes (as defined by the WHO as hospitalization and death)
reporting the use of antipsychotics.
Causality assessment
Each VigiBase ICSR with rhabdomyolysis, co-reported with and
without NMS, and published case report within our case series
analysis was assessed for causality between the antipsychotic
medicine and rhabdomyolysis by an expert assessment panel con-
sisting of a clinical psychiatrist (SC), a pharmacoepidemiologist
(LW) and a clinical pharmacist (NI). The panelists reviewed each
case individually, using as tools the French imputability (Be´gaud
et al. 1985), Naranjo (Naranjo et al. 1981), and Jones algorithms
( Jones 1982) as well as their expertise, to make a final assignment
of causality according to the WHO definitions (Appendix A). Their
final causality assignments, which were anonymous, were screened
for disagreements by a separate investigator (NA). Any disagree-
ments between assessors were fed back to the panelist, who had the
possibility to revise their judgments. The final causality assignment
for each case was made by consensus following discussion by the
expert panel.
Table 1. Search Terms for Published Case Reports Concerning Children and Adolescents Reported
with Antipsychotic Medicines and Rhabdomyolysis
Subjects Drug Study design Adverse event
Children
or
Child
or
Paediatric
or
Pediatric
or
Juvenile
or
School child
or
Youth
or
Young
or
Adolescents
or
Adolescence
or
Teenage
AND Atypical antipsychotic drugs
or
New neuroleptic
or
Antipsychotic drugs
or
Second generation
Antipsychotics
or
Antipsychotics
or
Risperidone
or
Clozapine
or
Olanzapine
or
Aripiprazole
or
Quetiapine
or
Sertindole
or
Zotepine
or
Amisulpride
or
Haloperidol
or
Chlorpromazine
AND Case
or
Report
or
Case report
or
Case reports
AND Rhabdomyolysis
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Critical Review of Individual Case
Safety Reports in VigiBase
For this evaluation, the VigiBase ICSRs with rhabdomyolysis co-
reported with and without NMS and their corresponding original
reports were used, excluding any reports also found in the literature.
The following five areas were considered as particularly useful
clinical information in the context of our study: Circumstances pre-
ceding the reaction; underlying risk factors; physical examination and
laboratory test results; drug reaction time-to-onset; and treatment of
the reaction. The report content was assessed in detail, investigating
whether and where on the report the information was recorded.
Results
A total of 26 reports on children and adolescents were evaluated in
this study, of which 20 were recorded with rhabdomyolysis in the
abscence of NMS. Six published case reports (Yoshikawa et al. 2000;
Rosebraugh et al. 2001; Holtmann et al. 2003; Strawn et al. 2008;
Hung et al. 2009; Karakaya et al. 2010) and 22 individual VigiBase
ICSRs were retrieved, of which two overlapped with reports retrieved
from the literature (Rosebraugh et al. 2001; Strawn et al. 2008).
Twenty reports with rhabdomyolysis were judged not to concern
NMS (RM group). The six VigiBase ICSRs that co-reported NMS
(RM +NMS group) are accounted for separately in this article. The
analysis is in three parts and Table 2 displays the number and type
of the 26 reports that are included in each:
1. The 22 VigiBase ICSRs were included in the dispropor-
tionate reporting pattern analysis.
2. All 26 reports were included in the detailed case series
analysis, encompassing both the VigiBase ICSRs and pub-
lished case reports.
3. Eighteen VigiBase ICSRs were included in the critical re-
view of ICSRs, excluding the two overlapping published
case reports in the RM group as well as two ICSRs in the
RM+NMS group that originated from the literature (Hanft
et al. 2004; Watson et al. 2004).
Disproportionate Reporting Patterns in VigiBase
Rhabdomyolysis, with and without co-reported NMS, was dis-
proportionally more frequently reported for antipsychotics than the
overall reporting in each age group (Table 3). The lower limit of the
95% credibility interval of the observed-to-expected ratio (IC025)
for rhabdomyolysis reported without NMS for the child/adolescent
age group was higher than the corresponding value for the adult
group. In a subanalysis, lipid modifying agents were excluded
(mostly used by adults and commonly reported with rhabdomyo-
lysis) resulting in an increase of the IC025 for the adults from
IC025: 0.39 to IC025: 1.90, whereas the corresponding values for
the child/adolescent age group remained similar (changed from
IC025: 0.78 to IC025: 0.81).
Table 4 displays the relative reporting frequency of ICSRs for
rhabdomyolysis, co-reported with and without NMS, and any an-
tipsychotic substance, olanzapine, risperidone, and haloperidol
relative to the overall reporting of the drug group/drug for the
children/adolescents and for the adults. Rhabdomyolysis reported
without NMS was disproportionally more frequently reported for
Table 2. Number and Type of Reports Included in Each Part of the Analysis of Rhabdomyolysis Co-Reported
With and Without Neuroleptic Malignant Syndrome (NMS) for Children and Adolescents Taking Antipsychotic
Medicines, by VigiBase Individual Case Safety Reports (ICSRs) and Published Case Reports
Part of analysis
Total no.
reports
VigiBase and/or
published reports
No. reports:
rhabdomyolysis
No. reports:
rhabdomyolysis
co-reported with NMS
Disproportionate reporting pattern 22 VigiBase ICSRs 14 4
VigiBase ICSRs also published 2a 2c
Detailed case series analysis 26 VigiBase ICSRs 14 4
VigiBase ICSRs also published 2a 2c
Published reports (not included in VigiBase) 4b -
Critical review of VigiBase ICSRs 18 VigiBase ICSRs 14 4
aRosebraugh et al. 2001; Strawn et al. 2008, included in VigiBase dataset.
bYoshikawa et al. 2000; Holtmann et al. 2003; Hung et al. 2009; Karakaya et al. 2010, not included in VigiBase dataset.
cHanft et al. 2004; Watson et al. 2004, included in VigiBase dataset, not retrieved from literature search.
Table 3. Observed-to-Expected Ratios, Presented with the Information Component (IC) for the Reporting
of Antipsychotic Medicines and Rhabdomyolysis With and Without Neuroleptic Malignant Syndrome
(NMS) by Age Group (VigiBase Data up to February 2010)
Age group (years) Defined ADR
Observed
no. reports
Calculated expected
no. reports IC IC025a
2 to 17 Rhabdomyolysis not NMS 16 5.1 1.57 0.78
Rhabdomyolysis co-reported with NMS 6 0.2 3.29 1.91
‡18 Rhabdomyolysis not NMS 566 397.1 0.51 0.39
Rhabdomyolysis co-reported with NMS 149 7.7 4.19 3.95
aThe lower limit of the 95% credibility interval of the shrinkage observed-to-expected ratio (IC025) > 0 indicates disproportional reporting relative to
the background of all reports with any drug in the age group.
ADR, adverse drug reaction.
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olanzapine (0.90%) relative to the overall reporting of the defined
term with antipsychotic medicines for children and adolescents
(0.18%).
Detailed Case Series Analysis of VigiBase Individual
Case Safety Reports and Published Case Reports
Patient demographics
The 26 VigiBase ICSRs and published case reports originated
from eight countries, of which 15 reports came from the United
States. Patient demographics are summarized for reports with
known values and displayed in Table 5, with the total 26 patients as
one group and also rhabdomyolysis with and without co-reported
NMS separately.
Weight (but not height) was recorded for 9 patients. One 17-
year-old male (RM +NMS) presented as being overweight and a
second 16-year-old male (RM group) appeared to be overweight
but its presentation was less obvious.
Suspected medicines
For 14 of the 20 cases in the RM group, the antipsychotic
medicine(s) was reported as the only suspected drug(s) for rhab-
domyolysis. In six reports, additional drugs other than antipsy-
chotic medicines were co-suspected. For the RM +NMS group,
three of the six reports included an antipsychotic medicine as
a single suspected drug. The suspected drugs are displayed in
Table 6.
Causality assessment
The 26 reports were assessed for causality by an expert panel. In
the final consensus round, there was a full agreement of which
WHO causality criteria to assign to each individual case. See Table 7
with the distribution of cases for each causality criterion used.
Clinical features
In the RM group, signs and symptoms preceding rhabdomyo-
lysis as well as those presented on the day of diagnosis were
specified in 17 reports (Table 8). Twelve cases had aches and pain,
of which abdominal pain/cramps and general muscle pain were the
most common.
Laboratory parameters
The creatine kinase (CPK/CK) values were specified in 15/20
reports in the RM group and the peak CPK/CK ranged from 858 to
95,000 U/L. In the RM +NMS group, values for 5/6 reports were
Table 4. Number and Percentage of the Three Most Frequently Reported Antipsychotic Drug Substances
Among Individual Case Safety Reports (ICSRs) for Children and Adolescents with Rhabdomyolysis Co-Reported
With and Without Neuroleptic Malignant Syndrome (NMS) and Antipsychotic Drugs,
Presented by Age Group (VigiBase Data up to February 2010)
Age group Any antipsychotic drug Olanzapine Risperidone Haloperidol
(years) Defined ADR no. reports (%) no. reports (%) no. reports (%) no.reports (%)
2 to 17 Rhabdomyolysis not NMS 16 (0.18) 9 (0.90)a 4 (0.20) 2 (0.29)
Rhabdomyolysis co-reported with NMS 6 (0.07) 2 (0.20) 1 (0.05) 2 (0.29)
Any ADR (total drug) 9095 1003 2014 680
‡18 Rhabdomyolysis not NMS 566 (0.38) 141 (0.80)a 97 (0.55)a 49 (0.46)
Rhabdomyolysis co-reported with NMS 149 (0.10) 40 (0.23)a 18 (0.10) 29 (0.27)a
Any ADR (total drug) 149,580 17,700 17,717 10,591
Percentage = number of reports for each defined ADR and drug/total number of reports for the drug in age group.
aThe lower limit of the 95% credibility interval of the shrinkage observed-to-expected ratio is > 0, indicating disproportional reporting relative to the
background of all reports of antipsychotic drug substances with the defined ADR in the age group.
ADR, adverse drug reaction.
Table 5. Patient Demographics for the 26 Children and Adolescents Reported with Antipsychotic Medicines
and Rhabdomyolysis With and Without Neuroleptic Malignant Syndrome (NMS)
All reports in case series Rhabdomyolysis
Rhabdomyolysis
co-reported with NMS
No. reports 26 20 6
Median age (range) 14.5 (5 to 17) 14.5 (6 to 17) 14.5 (5 to 17)
Males 21 (81%) 16 (80%) 5 (83%)
Ethnic origin
(specified in 8 reports)
Caucasian (n= 4),
African American (n= 3),
Asian (n= 1)
Caucasian (n= 4),
African American (n= 2),
Asian (n= 1)
African American
(n= 1).
Most frequently reported
indications (indication
was specified in a total
of 22 reports)a
Schizophrenia (n = 6),
bipolar disorder (n = 5),
psychosis (n = 4), obsessive
compulsive disorder (n= 3),
aggression (n= 2), ADHD (n= 2)
Bipolar disorder (n = 5),
schizophrenia (n= 4),
obsessive compulsive
disorder (n = 3), psychosis (n = 2),
aggression (n= 2), ADHD (n= 2)
Schizophrenia (n= 2),
psychosis (n= 2)
aOne report can contain more than one stated indication.
ADHD, attention deficit hyperactivity disorder.
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given; the peak CPKs ranged from 1373 to 77,330 U/L. The cases
with the lowest and highest CPK/CK values are presented subse-
quently. A CK of 858 U/L was recorded for a 6-year-old boy
(Yoshikawa et al. 2000). This boy had stopped haloperidol 2 days
prior to the CK test because of a suspected ‘‘mild rhabdomyolysis’’
when his urine myoglobin had been measured to 660 ng/mL. The CPK
value of 95,000 was detected by a primary care physician in a 17-year-
old male, who complained of lower back pain and dark brown urine.
The patient had been treated with a daily dose of risperidone 2.5 mg
for an unknown duration, which ‘‘recently had been increased to
4 mg.’’ The patient was admitted to the hospital, risperidone was
stopped, and he was treated with intravenous fluids. Myoglobin in the
urine was never detected. He recovered and was discharged with a
CPK of 8100 U/L and was prescribed fluoxetine 30 mg once daily.
Further information for this case is given in Table 9 and case 5.
In eight reports, myoglobin was detected in urine, ranging be-
tween 660 and 5930 ng/mL for the three cases with a known value.
Myoglobinemia was recorded for one case and in an additional two
cases, myoglobin was recorded without reference to urine or
plasma.
Time of drug start to onset of the event
The time period from start of antipsychotic treatment to onset of
symptoms or diagnosis of rhabdomyolysis could be determined in
16 reports in the RM group ranging from 2 days to 1.5 years, and is
displayed in Table 10, categorized according to records of possible
triggering factors at the time of event. In the RM +NMS group, the
time to onset ranged from 3 days to 1.5 months (3, 5, 5, 7, 48 days),
although the report with longer latency included very limited case
information.
Underlying risk factors for rhabdomyolysis
Underlying risk factors for rhabdomyolysis in the RM group
were recorded for nine patients: strenuous physical activity (n= 3),
seizure/hysterical seizure (n= 2), intramuscular (IM) injection
(n = 2), diabetic ketoacidosis (n = 1), alcohol use (n= 1), hyper-
thermia (n = 1), and possible infection (n= 1). Two patients had
more than one risk factor. The two cases with IM injections pre-
sented with unstable psychiatric disorders at the time of diagnosis
(Hung et al. 2009; Karakaya et al. 2010).
Underlying risk factors could not be excluded for three addi-
tional cases. One patient (severely disabled) had a medical history
of seizures, but these were not reported as uncontrolled at the time
of rhabdomyolysis. Two patients were taking antiepileptic medi-
cines with an unspecified indication.
Daily doses and route of administration
Daily doses for the antipsychotic medicines were specified in 20
of the 26 reports. Five of the cases with rhabdomyolysis reported
without NMS were recorded with doses in the higher range for their
age according to DRUGDEX (DRUGDEX System); for two of
these patients, onset of rhabdomyolysis occurred during dose in-
crease. See Table 9 for case details.
The antipsychotic medicines were administered orally, with the
exception of two cases in which IM administration had been used.
Both of these cases originated from two published case reports
(Hung et al. 2009; Karakaya et al. 2010). In one case, the patient
was switched from a 3 week treatment of risperidone 3 mg/day to
oral olanzapine 10 mg followed by 5 mg IM injection the next day,
after which the patient experienced hypothermia and rhabdomyo-
lysis (Hung et al. 2009). The other case received 10 mg olanzapine
IM and then 10 mg as maintenance therapy (Karakaya et al. 2010).
The patient only received two doses before being admitted to the
hospital for rhabdomyolysis.
Table 6. Suspected Drug Substances for the 26 Children and Adolescents Reported with Antipsychotic Medicines
and Rhabdomyolysis With and Without Neuroleptic Malignant Syndrome (NMS)
Rhabdomyolysis
Rhabdomyolysis co-reported
with NMS
Single and co-suspected
antipsychotic medicine(s)
Olanzapine (n= 6); risperidone (n = 3);
haloperidol (n= 1); paliperidone (n = 1);
quetiapine (n= 1); risperidone + haloperidol
(n= 1); risperidone + olanzapine (n = 1).
Cyamemazine (n= 1); olanzapine (n= 1);
ziprasidone (n= 1).
Co-suspected medicines other
than antipsychotics
Fluvoxamine + olanzapine (n= 1);
olanzapine + lithium (n= 1)a;
olanzapine + topiramate (n= 1)b;
clozapine + benzatropine (n = 1);
olanzapine + cyamemazine + valproate
sodium + haloperidol (n= 1);
aripiprazole + venlafaxine + risperidone+
topiramate + zonisamide (n = 1).
Haloperidol + trihexyphenidyl +
tetrabenazine (n= 1); olanzapine +
divalproex sodium (n= 1);
chlorpromazine + lorazepam +
risperidone + diphenhydramine +
haloperidol (n= 1).
Medicines separated with a ‘‘+ ’’ were those co-suspected but not necessarily given simultaneously, although given close in time.
aThis report concerned olanzapine-induced rhabdomyolysis and litium-induced electrocardiogram (ECG) changes (Rosebraugh et al. 2001).
bThis report concerned hyperthermia and rhabdomyolysis (Strawn et al. 2008).
Table 7. Number of Cases by Causality Criteria for the 26
Children and Adolescents Reported with Antipsychotic
Medicines and Rhabdomyolysis With and Without
Neuroleptic Malignant Syndrome (NMS)
WHO causality
criteria
No. reports
with rhabdomyolysis
No. reports with
rhabdomyolysis
co-reported with NMS
Probable/Likely 9 3
Possible 9 3
Not assessable 2 -
WHO, World Health Organization.
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Concomitant drugs
Apart from the co-suspected drugs (Table 6), commonly re-
ported concomitant drugs were antiepileptic medicines (n= 5 for
RM group; n= 2 for RM +NMS group) and antidepressants (n = 3
for RM group; n = 1 for RM +NMS group).
In the RM group, the number of reported drugs (irrespective of
whether they were reported as suspected or concomitant) ranged
from one to six drugs with a median of two recorded drugs per
report. In the RM+NMS group, the number of reported drugs
ranged from 1 to 11 drugs with a median of 4.5 drugs.
Withdrawal of treatment, outcome,
and seriousness of the event
The antipsychotic medicine was stated to have been withdrawn in
all reports. Twenty-one of the 26 patients recovered. Of the 20
patients in the RM group, 16 recovered/were recovering on the day
of report and 5 of the 6 cases recovered in the RM+NMS group.
Four reports included limited follow-up information, of which one
report concerned a 13-year-old male with the following record ‘‘the
patient developed rhabdomyolysis and had to have one of his legs
amputated.’’ In another report for a 15-year-old male with pancre-
atitis, diabetic ketoacidosis, and rhabdomyolysis, it was stated that
the patient recovered from the acute event but that the ‘‘patient may
have permanent damage’’. In two reports, the 17-year-old males
with renal complications had not recovered on the day of report. An
8-year-old female co-reported with NMS died of multi-organ fail-
ure. This report originated from a poison control center and was
accounted for in the 2003 annual report of the American Association
of Poison Control Centers Toxic Exposure Surveillance System
(Watson et al. 2004). Rhabdomyolysis resulted in renal problems in
three of the patients in the RM group, detailed in Table 9.
In all but two cases among the 26 reports, the patients were
hospitalized or their hospitalization was prolonged. In two Vigi-
Base ICSRs, it was not specified whether the patient had been
hospitalized.
Critical Review of Individual Case Safety
Reports in VigiBase
Eighteen original VigiBase ICSRs files of rhabdomyolysis with
and without NMS were evaluated for clinical usefulness (published
case reports and the poison control abstract were excluded) with
results displayed in Table 11.
Table 8. Signs and Symptoms Preceding Diagnosis, or Presented on Day of Rhabdomyolysis, Reported Without
Neuroleptic Malignant Syndrome, for Children and Adolescents Taking Antipsychotic Medicines
Signs and symptoms
Time prior
to diagnosis Age/Sex Aches and pain Movement symptoms Signs Other
1 day 17/M Lower back (DD) Decreased mobility Anuria, dark urine (DD)
2 days 15/F Abdominal (DD) Slight CK increase Vomiting (DD)
4–5 days 6/M Abdominal, back Seizures
15/M Abdominal Lethargy
16/M Abdominal, arms, leg
and chest cramps,
muscle aches
Dark urine (DD) Diaphoresis, diarrhea,
vomiting
(2 day prior)
17/Ma Facial myalgia Restless Slight CK increase
1–2 weeks 9/M Leg pain (DD) Walking problems (DD) Mild fever
(abated before
diagnosis)
Dizziness
(abated before
diagnosis)
15/M Muscle Fatigue
17/Mb Rash, bullous
eruption (DD)
3 weeks 13/Mc Muscle pain, sore throat,
abdominal cramps
Walking problems (DD) Weakness, diaphoresis
2 months (symptoms
on and off)
6/Md Dark urine
Day of diagnosis 12/M Headache Dark urine
13/Me Muscle tenderness Restless, stereotypical
movements,
head banging
14/F Abdominal
14/Ff High fever, hypotensive,
sinus tachycardia
Unresponsive
17/F Atrial fibrillation
17/Mg Hypothermic, hypotensive Drowsy, drooling
Each row represents the events for the 17 cases with this information specified.
aHoltmann et al. 2003.
bReported with rhabdomyolsis and/or bullous eruption (Case 1 in Table 9).
cRosebraugh et al. 2001.
dYoshikawa et al. 2000.
eKarakaya et al. 2010.
fStrawn et al. 2008.
gHung et al. 2009.
CK, creatine kinase; DD, day of diagnos.
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Discussion
Clinical features and possible risk factors
of rhabdomyolysis in children and adolescents
receiving antipsychotics
In this study, 20 reports of children and adolescents with rhab-
domyolysis in the absence of NMS, who had been treated with
antipsychotic medicines, are described. Abdominal pain or cramps
and muscle pains were common symptoms recorded during the
week preceding the diagnosis of rhabdomyolysis. Four cases had
abdominal pain prior to the rhabdomyolysis diagnosis and two
additional cases presented with abdominal pain at the time of di-
agnosis (of which one had recently completed a set of extensive sit-
ups). Abdominal pain has not been described as a typical clinical
symptom of rhabdomyolysis. However, in a chart review of chil-
dren and adolescents with rhabdomyolysis from any cause, 12% of
the 191 cases presented with abdominal tenderness (Mannix et al.
2006). Abdominal pain could have been an innocent bystander
in our case series because of its common occurrence in youth
(Gieteling et al. 2011). However, rhabdomyolysis is a serious ADR,
and unexpected abdominal pain should still serve as an alert for
further investigation to eliminate the possibility of emerging rhab-
domyolysis in a child or adolescent treated with antipsychotics.
Rhabdomyolysis was reported more frequently with olanzapine
relative to reports on all children and adolescents with antipsy-
chotic medicines in VigiBase. The higher reporting for olanzapine
in our case series could be the result of reporting bias from pub-
lished case reports on olanzapine (Rosebraugh et al. 2001; Strawn
et al. 2008; Hung et al. 2009; Karakaya et al. 2010), although three
of these case reports were published in or after 2008, whereas all
but one of the VigiBase ICSRs on olanzapine in our case series
were reported before that year. The reason for the higher reporting
for olanzapine could also be that it is more prone to induce rhab-
domyolysis than are other antipsychotics.
Ribeyron et al. reviewed 21 published and reported cases on
olanzapine and rhabdomyolysis from the French pharmacov-
igilance database, mainly in adults (Ribeyron et al. 2009). Two
cases in the French study overlapped with two cases described here,
one published case report (Rosebraugh et al. 2001) and one Vigi-
Base case. The overall results in the French study and in our study
corresponded, although the upper range of CPK was higher for the
subjects in our study. A possible explanation for the overall cor-
responding pattern between youth and adult reports could be that
Table 10. Time to Onset for Rhabdomyolysis Reported
Without Neuroleptic Malignant Syndrome After
Start of Antipsychotic Medicines for Children
and Adolescents, Where Time Latency
Could be Determined
Time
to onset
Possible triggering factors
for rhabdomyolysis recorded
No.
reports
2 days Intramuscular injections and
unstable psychiatric disease
2
3–7 days Other antipsychotic added 2
Dose increase (lower dose
used 6 months)
1
None recorded 1
> 1–3 weeks Concomitant underlying risk
factorsa
1
None recorded 3
1–2 months Concomitant underlying risk
factorsb
4
None recorded 1
1.5 years None recorded 1
aPossible infection.
bHysterical seizures and intensive sit-ups; strenuous activity and
hyperthermia; diabetic ketoacidosis; seizure.
Table 11. Categorization of Selected Clinical Information on 18 VigiBase Individual Case Safety Reports Using
Original Files, (Published Case Reports Excluded) for Children and Adolescents with Antipsychotic
Medicines and Rhabdomyolysis With and Without Neuroleptic Malignant Syndrome
Report information category No. reports Structured (searchable) data Free text
Circumstances preceding the
reaction (where information
was available)
8 Listed as reaction: n = 5
Some of the reactions are listed: n = 1
None of the reactions are listed: n = 2
n = 8
The listed preceding reactions had the same
onset date as rhabdomyolysis.
Underlying risk factors for
rhabdomyolysis(excluding
4 NMS cases)
6 Listed as an ADR, convulsion: n= 1 n = 6
Physical examination
or laboratory tests
16 of which
13 included
values
CPK increase: n= 4
Other laboratory abnormalities: n = 4
Myoglobinuria: n= 0
Pyrexia: n = 2
CPK/CK: n = 14 (with values: n = 12)
Other laboratory abnormalities:
n = 9 (with values: n= 5)
Myoglobinuria: n= 5
Myoglobin in urine or serum: n= 1
(with value)
Myoglobinemia: n = 1 (with value)
Temperature: n= 5 (one stated ‘‘no
fever’’)
Reaction time-to-onset 13 n= 9 n= 4 (only free text)
Treatment of the reaction
(other than hospitalization
or stopping the drug)
5 - n = 5
CPK, creatine phosphokinase; CK, creatine kinase, NMS, neuroleptic malignant syndrome; ADR, adverse drug reaction.
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the median age was 14.5 in our study, and therefore near the adult
group in age.
Rhabdomyolysis in association with antipsychotic use is re-
corded as occurring only rarely (Summary of Product Character-
istics [U.K.] 2012). The rarity and unspecific early symptoms of
rhabdomyolysis might contribute to the difficulty of recognizing
this as a drug-induced reaction. In one case, a boy had troubles with
weakness and walking problems over 4 weeks, which was inter-
preted by resident care staff as disobedience, before being re-
cognised as ADRs (Rosebraugh et al. 2001). In another case, a
mother noticed her son passing tea-coloured urine on and off for 2
months before she consulted healthcare professionals (Yoshikawa
et al. 2000). The time period between the antipsychotic start and
onset of rhabdomyolysis could range up to 2 months, as seen in our
study, possibly reducing the likelihood of suspecting the antipsy-
chotic as the causative agent. Hence, rhabdomyolysis might not
only be difficult to recognize but also less likely to be reported as an
ADR. On the other hand, NMS occurred within a week of the
antipsychotic start, as indicated by four of the six cases of rhab-
domyolysis co-reported with NMS in our case series.
In several of the studied cases, the onset of rhabdomyolysis oc-
curred in connection with a dose increase or when antipsychotic
medicines were switched or added to the patient’s drug regimen.
Exposure to known risk factors for rhabdomyolysis, such as intra-
muscular injection, alcohol use, and strenuous physical activity,
could have played a role in developing rhabdomyolysis in some of
our cases. Concomitant conditions such as seizures or an uncon-
trolled psychiatric disease, particularly with manic symptoms, could
also be reasons for developing or precipitating rhabdomyolysis.
Many of the cases in our review could have been influenced by such
risk factors when considering underlying disease. Nevertheless, the
majority of patients improved when the drug was withdrawn, sug-
gesting a causal relationship between the antipsychotic medicine
and rhabdomyolysis. The use of antipsychotic medicines in com-
bination with these factors could have triggered the development of
rhabdomyolysis in our cases, as the syndrome often presents itself
with more than one etiological factor (Melli et al. 2005).
Strengths and limitations of the study
This study gives a collected and detailed picture of how children
and adolescents can present with antipsychotic-induced rhabdo-
myolysis. The information aims to increase awareness of the fea-
tures of this rare ADR in clinical practice, and thereby enhance the
chances of capturing the early symptoms of rhabdomyolysis in
order to prevent the development of serious consequences for this
vulnerable patient group. We chose to restrict our search to reports
with a high degree of likelihood that the report was specific for
rhabdomyolysis. Because of this approach, there were a limited
number of reports in this case series; therefore, the findings in this
study cannot be used quantitatively. VigiBase does not include
denominator information for the reported drugs, and the reporting
system suffers from underreporting (Hazell et al. 2006); hence, we
cannot give the prevalence of rhabdomyolysis in association with
antipsychotic medicines for children and adolescents. Other limi-
tations of the reporting system are that recommendations and re-
quirements for reporting ICSRs vary among countries, and also,
that the amount of information given, as well as the likelihood that a
medicine caused the ADR, may vary from case to case. On the other
hand, in a recent published cohort study of 2767 child and ado-
lescent patients on antipsychotic drugs, no case of rhabdomyolysis
was identified (Rani et al. 2011), as the prevalence of antipsychotic
drug use in children is very low and a cohort study is often too small
to capture this rare ADR.
In this case series analysis, the ICSRs were found to contribute
with useful clinical information in addition to the published cases.
The availability of case narratives was crucial to capture infor-
mation describing which events preceded rhabdomyolysis and
when they occurred, underlying risk factors, laboratory values, and
treatment of the reaction. However, the information recorded on the
reports regarding underlying risk factors and treatment of the re-
action was sparse despite access to a narrative. More work and
education are needed not only to increase reporting but also to
enhance the amount and quality of case details on ICSRs.
Conclusion
Monitoring of children and adolescents needs to be intensified
during dose increases, when a new, added, or switched antipsychotic
medicine is introduced to their drug regimen and during exposure to
known risk factors for rhabdomyolysis. During antipsychotic
treatment, it is important to follow up unexpected signs and
symptoms not usually present in the individual patient. The devel-
opment of seemingly nonserious events such as abdominal pain,
muscle pain, weakness, and dark urine should be investigated during
antipsychotic use, as they might be precursory events to rhabdo-
myolysis that eventually could develop into acute renal failure.
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Appendix A
World Health Organization-Uppsala Monitoring Centre Causality Categories
Causality term Assessment criteria
Certain  Event or laboratory test abnormality, with plausible time relationship to drug intake
 Cannot be explained by disease or other drugs
 Response to withdrawal plausible (pharmacologically, pathologically)
 Event definitive pharmacologically or phenomenologically (i.e., an objective and specific
medical disorder or a recognized pharmacological phenomenon)
 Rechallenge satisfactory, if necessary
Probable/Likely  Event of laboratory test abnormality, with reasonable time relationship to drug intake
 Unlikely to be attributed to disease or other drugs
 Response to withdrawal clinically reasonable
 Rechallenge not required
Possible  Event or laboratory test abnormality, with reasonable time relationship to drug intake
 Could also be explained by disease or other drugs
 Information on drug withdrawal may be lacking or unclear
Unlikely  Event or laboratory test abnormality, with a time to drug intake that makes a relationship
improbable (but not impossible)
 Disease or other drugs provide plausible explanations
Conditional / Unclassified  Event or laboratory test abnormality
 More data for proper assessment needed, or
 Additional data under examination
Unassessable / Unclassifiable  Report suggesting an adverse reaction
 Cannot be judged because information is insufficient or contradictory
 Data cannot be supplemented or verified
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